Exploiting a PAX3-FOXO1-induced synthetic lethal ATR dependency for rhabdomyosarcoma therapy

Autor: García, H.D., Bei, Y., von Stebut, J., Ibáñez, G., Imami, K., Gürgen, D., Rolff, J., Helmsauer, K., Timme, N., Bardinet, V., Chamorro González, R., MacArthur, I.C., Pusch, F.F., Chen, C.Y., Schulz, J., Wengner, A.M., Furth, C., Lala, B., Eggert, A., Seifert, G., Hundsoerfer, P., Kirchner, M., Mertins, P., Selbach, M., Lissat, A., Schulte, J.H., Haase, K., Scheer, M., Ortiz, M.V., Henssen, A.G.

Pathognomonic PAX3-FOXO1 fusion oncogene expression is associated with poor outcome in rhabdomyosarcoma. Combining genome-wide CRISPR screening with cell-based functional genetic approaches, we here provide evidence that PAX3-FOXO1 induces replicatio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=mdc______med::bb5a940f992b1dd21f52c112b0042f4b
http://edoc.mdc-berlin.de/19709/1/19709oa.pdf

Therapeutic targeting of ATR in alveolar rhabdomyosarcoma.

Autor: Dorado García H; Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin, Berlin, Germany.; Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.; Max Delbrück Center for Molecular Medicine, Berlin, Germany., Pusch F; Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin, Berlin, Germany., Bei Y; Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin, Berlin, Germany.; Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.; Max Delbrück Center for Molecular Medicine, Berlin, Germany., von Stebut J; Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin, Berlin, Germany.; Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany., Ibáñez G; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Guillan K; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Imami K; Max Delbrück Center for Molecular Medicine, Berlin, Germany., Gürgen D; Experimental Pharmacology and Oncology (EPO), Berlin, Germany., Rolff J; Experimental Pharmacology and Oncology (EPO), Berlin, Germany., Helmsauer K; Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin, Berlin, Germany.; Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany., Meyer-Liesener S; Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin, Berlin, Germany.; Max Delbrück Center for Molecular Medicine, Berlin, Germany.; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Experimental and Clinical Research Center, Charité Campus Buch, Lindenberger Weg 80, 13125, Berlin, Germany., Timme N; Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany., Bardinet V; Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin, Berlin, Germany.; Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany., Chamorro González R; Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin, Berlin, Germany.; Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.; Max Delbrück Center for Molecular Medicine, Berlin, Germany., MacArthur IC; Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany., Chen CY; Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin, Berlin, Germany.; Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany., Schulz J; Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany., Wengner AM; Bayer AG, Berlin, Germany., Furth C; Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany., Lala B; Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany., Eggert A; Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany., Seifert G; Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany., Hundsoerfer P; Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany., Kirchner M; Max Delbrück Center for Molecular Medicine, Berlin, Germany.; Berlin Institute of Health, 10178, Berlin, Germany., Mertins P; Max Delbrück Center for Molecular Medicine, Berlin, Germany.; Berlin Institute of Health, 10178, Berlin, Germany., Selbach M; Max Delbrück Center for Molecular Medicine, Berlin, Germany., Lissat A; Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany., Dubois F; Institute of pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Junior Clinician Scientist Program, Charitéplatz 1, 10117, Berlin, Germany., Horst D; Institute of pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany., Schulte JH; Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany., Spuler S; Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin, Berlin, Germany.; Max Delbrück Center for Molecular Medicine, Berlin, Germany.; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Experimental and Clinical Research Center, Charité Campus Buch, Lindenberger Weg 80, 13125, Berlin, Germany.; Berlin Institute of Health, 10178, Berlin, Germany.; Department of chemistry, biochemistry and pharmacy, Free University of Berlin, Berlin, Germany., You D; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Dela Cruz F; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Kung AL; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Haase K; Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin, Berlin, Germany., DiVirgilio M; Max Delbrück Center for Molecular Medicine, Berlin, Germany., Scheer M; Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany., Ortiz MV; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Henssen AG; Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin, Berlin, Germany. henssenlab@gmail.com.; Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany. henssenlab@gmail.com.; Max Delbrück Center for Molecular Medicine, Berlin, Germany. henssenlab@gmail.com.; Berlin Institute of Health, 10178, Berlin, Germany. henssenlab@gmail.com.; German Cancer Consortium (DKTK), partner site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany. henssenlab@gmail.com.

Publikováno v: Nature communications [Nat Commun] 2022 Jul 25; Vol. 13 (1), pp. 4297. Date of Electronic Publication: 2022 Jul 25.

Current Controversy on Platelets and Patent Ductus Arteriosus Closure in Preterm Infants.

Autor: Sallmon H; Department of Pediatric Cardiology, Charité University Medical Center, Berlin, Germany.; Department of Congenital Heart Disease/Pediatric Cardiology, Deutsches Herzzentrum Berlin (DHZB), Berlin, Germany., Timme N; Department of Pediatric Cardiology, Charité University Medical Center, Berlin, Germany., Atasay B; Division of Neonatology, Department of Pediatrics, Ankara University School of Medicine, Ankara, Turkey., Erdeve Ö; Division of Neonatology, Department of Pediatrics, Ankara University School of Medicine, Ankara, Turkey., Hansmann G; Department of Pediatric Cardiology and Intensive Care Medicine, Medizinische Hochschule Hannover, Hanover, Germany., Singh Y; Department of Neonatology and Pediatric Cardiology, Cambridge University Hospitals, Cambridge, United Kingdom.; University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom., Weber SC; Department of Pediatric Cardiology, Charité University Medical Center, Berlin, Germany., Shelton EL; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, United States.; Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN, United States.

Publikováno v: Frontiers in pediatrics [Front Pediatr] 2021 Feb 25; Vol. 9, pp. 612242. Date of Electronic Publication: 2021 Feb 25 (Print Publication: 2021).

Small-Molecule Dual PLK1 and BRD4 Inhibitors are Active Against Preclinical Models of Pediatric Solid Tumors.

Autor: Timme N; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Experimental and Clinical Research Center (ECRC) of the Charité and the Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany., Han Y; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Experimental and Clinical Research Center (ECRC) of the Charité and the Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany., Liu S; Department of Chemistry, UMass Boston, Boston, MA, USA., Yosief HO; Department of Chemistry, UMass Boston, Boston, MA, USA., García HD; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Experimental and Clinical Research Center (ECRC) of the Charité and the Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany., Bei Y; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Experimental and Clinical Research Center (ECRC) of the Charité and the Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany., Klironomos F; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany., MacArthur IC; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Experimental and Clinical Research Center (ECRC) of the Charité and the Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany., Szymansky A; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Institute of Biology, Freie Universität Berlin, Germany., von Stebut J; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Experimental and Clinical Research Center (ECRC) of the Charité and the Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany., Bardinet V; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Experimental and Clinical Research Center (ECRC) of the Charité and the Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany., Dohna C; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany., Künkele A; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Deutsches Konsortium für Translationale Krebsforschung, Berlin, Germany., Rolff J; Experimental Pharmacology and Oncology Berlin-Buch GmbH (EPO), Berlin, Germany., Hundsdörfer P; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health, Berlin, Germany; Helios Klinikum Berlin-Buch, Germany., Lissat A; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany., Seifert G; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany., Eggert A; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany., Schulte JH; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Deutsches Konsortium für Translationale Krebsforschung, Berlin, Germany; Berlin Institute of Health, Berlin, Germany., Zhang W; Department of Chemistry, UMass Boston, Boston, MA, USA., Henssen AG; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Experimental and Clinical Research Center (ECRC) of the Charité and the Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany; Deutsches Konsortium für Translationale Krebsforschung, Berlin, Germany; Berlin Institute of Health, Berlin, Germany. Electronic address: anton.henssen@charite.de.

Publikováno v: Translational oncology [Transl Oncol] 2020 Feb; Vol. 13 (2), pp. 221-232. Date of Electronic Publication: 2019 Dec 21.

Milking a spherical cow: Toy models in neuroscience.

Autor: Beer RD; Cognitive Science Program, Indiana University, Bloomington, Indiana, USA.; Neuroscience Program, Indiana University, Bloomington, Indiana, USA.; Department of Informatics, Indiana University, Bloomington, Indiana, USA., Barwich AS; Cognitive Science Program, Indiana University, Bloomington, Indiana, USA.; Neuroscience Program, Indiana University, Bloomington, Indiana, USA.; Department of History and Philosophy of Science and Medicine, Indiana University, Bloomington, Indiana, USA., Severino GJ; Cognitive Science Program, Indiana University, Bloomington, Indiana, USA.

Publikováno v: The European journal of neuroscience [Eur J Neurosci] 2024 Nov; Vol. 60 (10), pp. 6359-6374. Date of Electronic Publication: 2024 Sep 11.